Tempus AI’s (TEM) Market Perform Rating Reiterated at William Blair

Tempus AI (NASDAQ:TEM)‘s stock had its “market perform” rating reiterated by stock analysts at William Blair in a research report issued to clients and investors on Tuesday,RTT News reports.

A number of other research firms have also recently weighed in on TEM. Loop Capital lowered their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Guggenheim reissued a “buy” rating on shares of Tempus AI in a research report on Tuesday. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Finally, TD Cowen reissued a “buy” rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.55.

Tempus AI Stock Down 17.0 %

Shares of NASDAQ:TEM traded down $11.82 during mid-day trading on Tuesday, reaching $57.75. 19,698,619 shares of the company were exchanged, compared to its average volume of 14,684,215. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The firm’s 50-day simple moving average is $50.88 and its 200 day simple moving average is $52.03. Tempus AI has a 1 year low of $22.89 and a 1 year high of $91.45.

Insider Activity

In related news, Director David R. Epstein sold 620 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the sale, the director now directly owns 27,894 shares in the company, valued at $1,166,248.14. This trade represents a 2.17 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric P. Lefkofsky sold 476,209 shares of Tempus AI stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total transaction of $23,734,256.56. Following the sale, the chief executive officer now owns 6,502,643 shares in the company, valued at $324,091,727.12. This represents a 6.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,583,467 shares of company stock worth $130,542,311.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Operose Advisors LLC acquired a new stake in Tempus AI during the 4th quarter worth $25,000. First Horizon Advisors Inc. acquired a new stake in Tempus AI during the 3rd quarter worth $30,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI during the 4th quarter worth $34,000. Prestige Wealth Management Group LLC grew its position in Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new position in Tempus AI during the 4th quarter worth $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.